tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Revolution Medicines: Differentiated RAS(ON) Pipeline Underpins Overweight/Buy Rating and $92 December 2026 Target
PremiumRatingsRevolution Medicines: Differentiated RAS(ON) Pipeline Underpins Overweight/Buy Rating and $92 December 2026 Target
27d ago
Revolution Medicines falls -17.1%
Premium
The Fly
Revolution Medicines falls -17.1%
28d ago
Revolution Medicines Advances RMC-5127 KRAS Program, Extending Its Oncology Reach
Premium
Company Announcements
Revolution Medicines Advances RMC-5127 KRAS Program, Extending Its Oncology Reach
28d ago
M&A News: Revolution Medicines (RVMD) Stock Plunges as Merck Ends Takeover Talks on Price Disagreement
PremiumMarket NewsM&A News: Revolution Medicines (RVMD) Stock Plunges as Merck Ends Takeover Talks on Price Disagreement
28d ago
Revolution Medicines: Post‑Merger Volatility Creates Compelling Entry Point Ahead of Blockbuster PDAC Opportunity and 2026 Catalysts
Premium
Ratings
Revolution Medicines: Post‑Merger Volatility Creates Compelling Entry Point Ahead of Blockbuster PDAC Opportunity and 2026 Catalysts
28d ago
Revolution Medicines buyers will step in on weakness, says Stifel
Premium
The Fly
Revolution Medicines buyers will step in on weakness, says Stifel
28d ago
Private Markets: SpaceX interviews banks to lead IPO, Skild AI raises $1.4B
PremiumThe FlyPrivate Markets: SpaceX interviews banks to lead IPO, Skild AI raises $1.4B
1M ago
Expanding RAS-Targeted Franchise and Late-Stage Pipeline Drive Buy Rating on Revolution Medicines
Premium
Ratings
Expanding RAS-Targeted Franchise and Late-Stage Pipeline Drive Buy Rating on Revolution Medicines
1M ago
Merck Sees $70B Revenue Potential From New Growth Drivers by Mid-2030s
Premium
Market News
Merck Sees $70B Revenue Potential From New Growth Drivers by Mid-2030s
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100